Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector by Guan, M. (Min) et al.
Increased Efficacy and Safety in the Treatment of Experimental Liver
Cancer with a Novel Adenovirus-Alphavirus Hybrid Vector
Min Guan,
1
Juan R. Rodriguez-Madoz,
1
Pilar Alzuguren,
1
Celia Gomar,
1
M. Gabriela Kramer,
1
Stefan Kochanek,
2
Jesus Prieto,
1
Cristian Smerdou,
1
and Cheng Qian
1
1Division of Hepatology and Gene Therapy, School of Medicine, Centro de Investigacio´n Me´dica Aplicada, University of Navarra, Pamplona,
Spain and 2Division of Gene Therapy, University of Ulm, Ulm, Germany
Abstract
An improved viral vector for cancer gene therapy should be
capable of infecting tumors with high efficiency, inducing
specific and high-level expression of transgene in the tumor
and selectively destroying tumor cells. In the design of such a
vector to treat hepatocellular carcinoma, we took advantage
of (a) the high infectivity of adenoviruses for hepatic cells, (b)
the high level of protein expression and proapoptotic
properties that characterize Semliki Forest virus (SFV)
replicon, and (c) tumor selectivity provided by A-fetoprotein
(AFP) promoter. We constructed a hybrid viral vector
composed of a helper-dependent adenovirus containing an
SFV replicon under the transcriptional control of AFP
promoter and a transgene driven by SFV subgenomic
promoter. Hybrid vectors containing murine interleukin-12
(mIL-12) genes or reporter gene LacZ showed very specific
and high-level expression of transgenes in AFP-expressing
hepatocellular carcinoma cells, both in vitro and in an in vivo
hepatocellular carcinoma animal model. Infected hepatocel-
lular carcinoma cells were selectively eliminated due to the
induction of apoptosis by SFV replication. In a rat orthotopic
liver tumor model, treatment of established tumors with a
hybrid vector carrying mIL-12 gene resulted in strong
antitumoral activity without accompanying toxicity. This
new type of hybrid vectors may provide a potent and safe
tool for cancer gene therapy. (Cancer Res 2006; 66(3): 1620-9)
Introduction
Gene therapy offers a new approach to treat cancer. Transfer of
genes encoding immunostimulatory cytokines, such as interleukin-
12 (IL-12), to tumors has been used with remarkable success to
eliminate cancer in animal models (1–4). This strategy allows to
concentrate the biological action of the cytokines at the site of the
neoplasm, thus increasing the antitumor effect while avoiding
systemic toxicity. Despite promising preclinical data (1–4), pilot
clinical trials in patients with liver cancer showed that intra-
tumoral administration of an adenoviral vector encoding IL-12
under the control of cytomegalovirus promoter (AdCMV-IL-12) had
limited efficacy with only one partial regression being observed
among eight treated patients with hepatocellular carcinoma (5).
This modest result was associated with low-level expression of the
transgene in the tumor mass and poor activation of antitumor
immunity (5).
Thus, vectors being able to generate high levels of transgenic
proteins in the tumor and of stimulating more intense antitumor
responses should be developed (6, 7). However, high-expression
vectors may increase the risk of toxicity; consequently, avoidance of
transgene expression at extratumoral sites is an absolute
requirement for the use of such gene therapy tools (6, 7). Tumor-
specific promoters allow transcriptional tumor targeting (8).
However, these are normally weak promoters that do not allow
high-level expression of the transgenic protein in the neoplastic
tissue (9–11). Thus, strategies to achieve both transcriptional
targeting and high-level expression of the transgene would be
necessary to treat cancer. On the other hand, when the transgene is
an immunostimulatory cytokine, the antitumor effect will be
enhanced if the vector is able to induce apoptosis in the neoplastic
cells. It has been shown that the release of apoptotic bodies in a
cytokine-rich milieu would favor the presentation of tumor
antigens and the induction of antitumor immunity (12, 13).
Therefore, combination of high infectivity for tumor cells, strict
tumor targeting, high production of the therapeutic protein inside
tumor, and induction of selective apoptosis of cancer cells are four
conditions for a vector to be successful against cancer in the
clinical setting. The objective of this study is to gain in efficacy
against hepatocellular carcinoma by combining in a single vector
high infectivity using an adenovirus delivery system, high level of
transgene expression and induction of apoptosis using an
alphavirus vector (14), and tumor specificity by placing the
alphavirus replicon under the transcriptional control of a tumor-
specific promoter.
Helper-dependent adenoviral vectors, also called high-capacity
(HC-Ad) or gutless adenoviruses, are adenovirus-based vectors
devoid of all adenoviral genes, thus leaving room to allocate
large expression cassettes (up to 35 kb), such as that corresponding
to an alphavirus replicon (15–17). Alphaviruses are RNA-enveloped
viruses that contain a single positive-strand RNA molecule
as genome (18). Different alphaviruses, such as Sindbis virus (19),
Semliki Forest virus (SFV; ref. 14), and Venezuelan Equine en-
cephalytis virus (20), have served for the construction of gene
therapy vectors. These are based on the use of self-replicating RNA
molecules derived from alphavirus genomes in which the 5Vand 3V
sequences necessary for replication and the replicase (Rep) gene
have been maintained, whereas the genes coding for the viral
structural proteins have been deleted and substituted by a
transgene. Upon transfecting the vector into a cell, Rep will be
translated and the vector RNA will be copied into a negative-strand
RNA that will be used as template for the amplification of the
vector RNA. Rep can also recognize a subgenomic promoter in the
negative-strand RNA from which it will make a smaller subgenomic
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RNA that can be translated to produce the heterologous protein.
Replication and expression of the transgene occur at very high
levels being the first one associated with the induction of apoptosis
in the infected cells (21).
We constructed a hybrid adenoviral vector that contains the
sequence of a recombinant SFV replicon under the transcrip-
tional control of a-fetoprotein (AFP) promoter (Fig. 1A-B). In
this construct, the SFV replicon contained the IL-12 gene driven
by the SFV subgenomic promoter. Our aim was to allow
replication of the SFV replicon, leading to high-level production
of IL-12 and apoptosis of the transduced cells only in AFP-
expressing hepatocellular carcinoma tumors, but not in other
cell types to gain in safety and efficacy in the treatment of liver
cancer.
Materials and Methods
Cell lines and tissue culture. Human hepatocellular carcinoma cell
lines Hep3B, PLC/PRF/5, and HepG2; human cervix epithelial adenocarci-
noma cell line HeLa; human lung carcinoma cell line A549; human tumor
cell line SK-Hep-1; human 293 cell line; rat hepatocellular carcinoma cell
lines McA-RH7777 and MHC1; and normal rat hepatocyte clone 9 were
obtained from American Type Culture Collection (Manassas, VA). 293 cells
expressing Cre recombinase (293Cre4) were obtained from Merck Research
Laboratories (West Point, PA).
Animals. Seven-week-old female BALB/c nude mice and BALB/c mice
were purchased from Charles Rivers Laboratories (Barcelona, Spain). Four-
to 6-week-old male Buffalo rats were obtained from Harlan (Barcelona,
Spain). The animals were kept under standard pathogen-free conditions and
were handled according to the criteria outlined in the Guide for the Care
and Use of Laboratory Animals by the National Academy of Sciences.
All experiments were done in accordance with the local animal ethical
committee.
Construction of hybrid vectors. The 5V-end sequence of SFV (1-292
nucleotides) was amplified by PCR using pBK-SFV plasmid (containing the
full sequence of SFV Rep) as template (22). Primer 1 contained an SpeI
restriction site at the 5Vend (underlined) followed by 50 nucleotides of AFP
promoter sequence and the first 20 nucleotides of the SFV sequence
(in italics) 5V-ACTAGTTAACAGGCATTGCCTGAAAAGAGTATAAAA-
GAATTTCAGCATGATTTTCCATGGCGGATGTGTGACATAC -3V. Primer 2
contained a XhoI restriction site (underlined) followed by 19 nucleotides
from SFV sequence (in italics): 5V-CTCGAGGATATCCAAGATGAGTGTGT-3V.
A DNA fragment of 351 bp was generated by PCR and cloned directly into
pGEM-T-easy plasmid (Promega, Madison, WI) to generate pGEM-Te-SFV-1.
The absence of PCR errors in this plasmid was confirmed by sequencing. A
347 bp fragment was released from pGEM-Te-SFV-1 by digestion with
SpeI and XhoI and cloned into pGL3/AFP digested with the same enzymes
to yield pGL3/AFP-SFV-1, which has a full AFP promoter (217 bp) and
enhancer (785 bp) followed by the SFV 5V-end sequence (SFV-1, comprising
292 bp). An AFP-SFV-1 (1,342 bp) cassette was released from pGL3/AFP-
SFV-1 by MluI/XhoI digestion, treated with Klenow and cloned into pBS-
SK+ digested with EcoRV, generating pBS/AFP-SFV-1. The SV40 late polyA
(262 bp) was removed from pGL3/AFP by XbaI/BamHI digestion, blunted
with Klenow, and inserted into the SalI site of pBS/AFP-SFV-1 also blunted
with Klenow, giving rise to pBS/AFP-SFV-1-pA. A polylinker containing both
unique ApaI and NruI sites was inserted between BamHI and XmaI sites in
pBS/AFP-SFV-1-pA. The 3V-end sequence of SFV comprising 7,985 bp was
removed by SpeI/EcoRV digestion from pBK-SFV, blunted with Klenow and
inserted into EcoRV digested pBS/AFP-SFV-1-pA, giving rise to pBS/AFP-
SFV-pA.
LacZ reporter gene was obtained from pCMVh (Clontech, Mountain
View, CA) by NotI digestion and inserted into the BamHI site of pBS/AFP-
SFV-pA to form pBS/AFP-SFV-LacZ-pA by blunt-end ligation. A mIL-12
cassette containing the genes coding for the p35 and p40 subunits linked by
the encephalomyocarditis virus internal ribosome entry site was removed
from pBS/mIL-12 (23) by SpeI/XhoI digestion, treated with Klenow, and
inserted into BamHI in pBS/AFP-SFVpA, also blunted with Klenow
generating pBS/AFP-SFV-mIL-12-pA.
The 19 kb fragment from gutless adenovirus plasmid pSTK120 (16)
was obtained by ApaI digestion and a polylinker containing AscI and
Figure 1. Diagram of gutless adenovirus-SFV hybrid vector and its potential
antitumoral activity. A, the hybrid vector contains a gutless adenovirus
sequence in which a SFV replicon has been inserted under the control of the AFP
promoter/enhancer (AFP ). The heterologous gene mIL-12 is placed under the
control of the SFV subgenomic promoter (sg Pr). B, upon infection of
hepatocellular carcinoma (HCC) cells (left) with the hybrid vector, the SFV
replicon mRNA can be transcribed from the tumor-specific promoter, Rep will be
translated, and copy SFV RNA genome (+) into negative-strand RNA (). Rep
will also synthesize a SFV subgenomic RNA from which mIL-12 will be
expressed at high levels. The mIL-12 secreted from infected cells will activate
immunocytes at the site of infection. In addition, SFV replication will also induce
apoptosis in infected cells, leading to the release of tumor antigens from
apoptotic cells, which can be taken up by antigen-presenting cells (APC ).
Presentation of tumor antigen by antigen-presenting cells and activation of
immunocytes by IL-12 will activate immune responses against the tumor.
However, if this hybrid vector infects normal cells (right), the SFV replicon
mRNA will not be transcribed and, therefore, neither transgene expression nor
apoptosis will occur. C, structure of gutless adenovirus vectors. HC-Ad-AFP-
SFV-LacZ and HC-Ad-AFP-SFV-mIL-12 are hybrid adenovirus vectors in
which the SFV replicon sequence is under the control of the AFP promoter/
enhancer and the heterologous genes LacZ or mIL-12 have been placed
downstream of the SFV subgenomic promoter, respectively. HC-Ad-AFP-LacZ
and HC-Ad-AFP-mIL-12 are gutless adenovirus vectors that contain LacZ or
mIL-12 driven directly by the AFP promoter/enhancer, respectively. ITR, inverted
terminal repeat; W, adenovirus packaging signal; HPRT, intron region of human
genomic hypoxanthine phosphoribosyltransferase as stuffer sequence; C346,
cosmid C346 human genomic as stuffer sequence.
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SbfI sites was inserted to form pTGC3001. The AFP-SFV-LacZ cassette
was removed by ApaI from pBS/AFP-SFV-LacZ-pA and inserted into the
ApaI site of pTGC3001, giving rise to pTGC3011. In a similar way, the
AFP-SFV-mIL-12 cassette was released from pBS/AFP-SFV-mIL-12-pA by
BssHII digestion and inserted into the AscI site of pTGC3001 to generate
pTGC3012.
Construction of control vectors. The AFP enhancer/promoter sequence
was removed byMluI + Klenow/XhoI digestion from pGL3/AFP and inserted
into pCMVh, which had been previously digested with EcoRI + Klenow/XhoI.
In this way, the CMV immediate early promoter was removed from pCMVh
and pAFPh was generated. The AFP-LacZ cassette (5,077 bp) was
subsequently removed from pAFPh by XbaI/NarI digestion and inserted
into the SwaI site of pSTK120, giving rise to pTGC3013 by blunt-end ligation.
The mIL-12 cassette was removed from pBS/mIL-12 by XhoI/SpeI
digestion and inserted into pGL3/AFP digested with XhoI/XbaI, which
removed the luciferase gene from the latter plasmid and gave rise to pAFP-
mIL-12. The AFP-mIL-12 cassette (3,760 bp) was released from pAFP-mIL-
12 by BamHI/ScaI digestion and inserted into SwaI-digested pSTK120,
generating pTGC3014 by blunt-end ligation.
SFV-mIL-12 vector has been described (24) and carries under the viral
subgenomic promoter a mIL-12 cassette containing the genes coding for
the p35 and p40 subunits linked by the encephalomyocarditis virus internal
ribosome entry site. SFV-mIL-12 and SFV-LacZ recombinant viral particles
were produced as previously described (25).
Rescue of gutless adenoviral vectors. Following PmeI digestion,
phenol/chloroform extraction, and ethanol precipitation, 2 Ag of pTGC3011,
pTGC3012, pTGC3013, or pTGC3014 DNA were transfected into 293Cre4
cells, respectively. After transfection, cells were infected with helper virus
AdLC8cluc. Subsequent amplification steps and large-scale preparations
were done as described previously (26). All vector preparations were
purified twice by CsCl equilibrium density centrifugation. The DNAs
from purified vectors were analyzed by restriction digestion and showed
no rearrangements. Titration of gutless adenovirus and helper virus
contamination was evaluated using quantitative PCR. The titers of HC-
Ad-AFP-LacZ, HC-Ad-AFP-SFV-LacZ, HC-Ad-AFP-mIL-12, and HC-Ad-AFP-
SFV-mIL-12 were 1.5  1012, 2.7  1011, 8.9  1012, and 2.1  1012 virus
particles (vp)/mL, respectively. Helper virus contamination of these vectors
was 1.2%, 4.1%, 0.6%, and 5% respectively.
Quantitative PCR. For determination of titers of gutless adenoviruses,
probes and primers for quantitative PCR of LacZ and mIL-12 sequences
were designed. Helper virus contamination was determined by quantitative
PCR using probes and primers specific for Ad5 E4 region and wild-type Ad
was determined by quantitative PCR with probes and primers specific
for Ad5 E1 region. All primers were designed by TaqMan program and
synthesized by Sigma-Genosys Ltd. (St. Louis, MO), and Applied Biosystems
(Foster City, CA).
Transgene expression in cells infected with gutless adenoviral
vectors. Cell lines were infected with each of gutless adenoviral vector
at viral particles per cell (ppc) 10, 100, or 1,000, respectively. A first-
generation adenovirus AdCMV-mIL-12 was used as control. Supernatants
from cells infected with mIL-12 vectors and cell lysates from cells infected
with LacZ vectors were collected from duplicate wells for determination
Figure 2. Specific expression of mIL-12 and h-galactosidase in hepatocellular carcinoma cells in vitro after infection with hybrid vectors. Four hepatocellular
carcinoma cell lines (Hep3B, Huh-7, HepG2, and PLC/PRF/5) with AFP expression (A ) and five hepatocellular carcinoma and non–hepatocellular carcinoma cell
lines without AFP expression (HeLa, A549, MHC1, Sk-Hep-1, and clone 9; B) were infected with HC-Ad-AFP-mIL-12, HC-Ad-AFP-SFV-mIL-12, or control vector
AdCMV-mIL-12 at different ppc (10, 100, and 1,000). After 2 days of infection, the supernatant was collected and the amount of mIL-12 was determined. C to F,
two hepatocellular carcinoma cell lines (Hep3B and Huh-7) were infected with HC-Ad-AFP-LacZ or HC-Ad-AFP-SFV-LacZ at ppc 1,000. After 2 days of infection,
the infected cells were stained with X-Gal. Microphotographs of cells infected with HC-Ad-AFP-LacZ (C and D) or HC-Ad-AFP-SFV-LacZ (E and F ). C and E,
Hep3B; D and F, Huh7.
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of mIL-12 and h-galactosidase levels, respectively. Cells infected with
LacZ vectors were also stained with 5-bromo-4-chloro-3-indolyl-h-D-
galactopyranoside (X-Gal). The mIL-12 level (p70) was measured with
an ELISA kit (PharMingen, San Diego, CA). h-galactosidase level was
measured with an ELISA kit (Roche, Basel, Switzerland). The time course
of mIL-12 expression was evaluated in hepatocellular carcinoma cells
after infection with HC-Ad-AFP-mIL-12, HC-Ad-AFP-SFV-mIL-12, or with
control vector AdCMV-mIL-12 at ppc 1,000. Supernatants were collected
daily until 5 days postinfection.
Cytotoxicity assay cell proliferation assay by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide incorporation. Hepatocellular
carcinoma cells were infected with gutless adenoviral vectors or AdCMV-
mIL-12 at ppc 1,000. Five days after infection, cell survival was determined
by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. Briefly, cells were washed once with PBS and 200 AL of freshly
prepared MTT dye solution were added per well (in 48-well plates). Cells
were further cultured for 3 to 4 hours followed by addition of 500 AL of
solubilization buffer. One hundred microliters of each sample were taken
for measurement of absorbance in a spectrophotometer at a wavelength
of 570 nm.
Detection of SFV Rep by immunofluorescence. Cells were seeded on
glass coverslips in six-well plates (1  105 per well) and infected with HC-
Ad-AFP-mIL-12, or HC-Ad-AFP-SFV-mIL-12 at ppc 1,000. Two days after
infection, coverslips were rinsed twice with PBS, and cells were fixed with
methanol at 20jC for 6 minutes. Coverslips were incubated with primary
antibody [monoclonal antibody (mAb) antireplicase, kindly provided by
Dr. W. Bodemer, Veterinary Medicine and Primate Husbandry, German
Primate Center, Goettingen, Germany] diluted 1:10 at room temperature for
30 minutes followed by incubation with the secondary antibody (FITC-
conjugated rabbit anti-mouse, Sigma) diluted 1:250 for 30 minutes. Finally,
coverslips were mounted on glass slides using Vecta shield with 4V,6-
diamidino-2-phenylindole (DAPI) to stain cell nuclei.
Detection of SFV RNA by Northern blot. Cells were seeded in six-well
plates (1  105 per well) and infected with HC-Ad-AFP-mIL-12, HC-Ad-AFP-
SFV-mIL-12 at ppc 1,000, or mock infected. Two days after infection, total
RNA was extracted by using RNeasy minikit (Qiagen, Hilden, Germany)
and analyzed by Northern blot. Three micrograms of total RNA were
size fractionated on a 1.2% agarose/formaldehyde gel, transferred to a
nitrocellulose membrane (Hybond-N+, Amersham), and hybridized to a
32P-labeled oligonucleotide specific for SFV subgenomic promoter (5V-
GAATTCTGTGTATTAACGCAC-3V) or to a 32P-labeled probe specific for
human h-actin (5V-CTGGTGCCTGGGGCG-3V). RNA extracted from baby
hamster kidney (BHK) cells infected with SFV-IL-12 at 24 hours postinfection
was used as positive control.
Induction of hepatocellular carcinoma xenograft and study of
in vivo gene transfer efficiency. Huh-7 cells (2  106) were injected s.c.
into the right flank of BALB/c nude mice. When tumors nodules reached 6 to
8 mm in diameter at 4 weeks after inoculation, 1  1010 vp of HC-Ad-AFP-
LacZ (n = 4) or HC-Ad-AFP-SFV-LacZ (n = 4) were injected intratumorally.
Mice were sacrificed at day 3 postinoculation to obtain tumor and liver
samples. Frozen tissues were sectioned for staining with X-Gal and terminal
deoxynucleotidyl transferase–mediated nick end labeling (TUNEL, Roche).
To study specificity of hybrid vectors in vivo , normal BALB/c mice were
injected i.v. with HC-Ad-AFP-LacZ (n = 4), HC-Ad-AFP-SFV-LacZ (n = 4), or
AdCMV-LacZ at 1  1010 vp/mouse. After 3 days, animals were sacrificed
and main organs were collected for LacZ expression analysis.
Induction of orthotopic hepatocellular carcinoma and in vivo gene
therapy. McA-RH7777 cells (5  105) were inoculated into the left liver lobe
of Buffalo rats. A single tumor nodule (7-10 mm in diameter) was observed
in each animal 10 days after inoculation of tumor cells. Tumors were
treated with 2  1011 vp of either HC-Ad-AFP-mIL-12, HC-Ad-AFP-SFV-
mIL-12, or with 108 IU of control vectors SFV-mIL-12 or SFV-LacZ. Two and
4 weeks after treatment, animals were anesthetized and underwent
laparotomy to observe the evolution of the tumor. Survival was checked
daily in all animals. Tumor size was determined by measuring the length
and width of each nodule and applying the formula: Tumor volume =
(length)  (width)2  0.5236.
Results
Characterization of hybrid vectors in vitro . Four gutless
adenoviral vectors have been constructed as shown in Fig. 1C . To
examine the specificity of transgene expression with the recombi-
nant vectors, four human hepatocellular carcinoma cell lines
(Hep3B, HepG2, Huh-7, and PLC/PRF/5) producing high levels of
AFP (27) and five cell lines (HeLa, A549, SK-Hep-1, MHC1, and
clone 9) that do not express AFP were infected with HC-Ad-AFP-
mIL-12, HC-Ad-AFP-SFV-mIL-12, or AdCMV-mIL-12 as a positive
control. No mIL-12 expression could be detected in human
hepatocellular carcinoma cells infected with HC-Ad-AFP-mIL-12
at ppc 10 or 100; a very low level of mIL-12 expression was
observed only at ppc 1,000 (Fig. 2A). In contrast, infection of
these cell lines with HC-Ad-AFP-SFV-mIL-12 at ppc 10, 100, or
1,000 resulted in mIL-12 expression in a dose-dependent manner
(Fig. 2A). The level of mIL-12 expression in cells infected with ppc
10 of HC-Ad-AFP-SFV-mIL-12 was comparable with the level
obtained in cells infected with HC-Ad-AFP-mIL-12 at ppc 1,000.
Moreover, the mIL-12 level obtained from hepatocellular carcino-
ma cells infected with HC-Ad-AFP-SFV-mIL-12 was comparable
with the one obtained with control vector AdCMV-mIL-12.
However, infection of cells that do not express AFP with HC-Ad-
AFP-mIL-12 or HC-Ad-AFP-SFV-mIL-12 did not result in detectable
mIL-12 production even when the highest ppc (1,000) was used
(Fig. 2B). In these cells, however, control vector AdCMV-mIL-12
induced production of high amounts of mIL-12. Similar data
were observed by quantification of h-galactosidase expression in
hepatocellular carcinoma cells infected with HC-Ad-AFP-LacZ or
HC-Ad-AFP-SFV-LacZ vectors (Supplementary Fig. S1). Represen-
tative microphotographs of hepatocellular carcinoma cells infected
with these vectors followed by staining with X-Gal are shown in Fig.
2C-F . Infection of hepatocellular carcinoma cells with HC-Ad-AFP-
LacZ resulted in a low percentage of infected cells with weak
staining (Fig. 2C and D). In contrast, infection of hepatocellular
carcinoma cells with HC-Ad-AFP-SFV-LacZ produced a high
percentage of strongly stained cells (Fig. 2E and F). Importantly,
HC-Ad-AFP-LacZ and HC-Ad-AFP-SFV-LacZ did not induce trans-
gene expression in non–hepatocellular carcinoma cells (data not
shown). These observations indicate that a hybrid vector carrying
an SFV replicon under the control of the AFP promoter/enhancer
can induce strong transgene expression specifically in AFP-
expressing tumor cells.
Kinetics of mIL-12 expression in hepatocellular carcinoma
cells in vitro . To study the kinetics of mIL-12 production after
infection of hepatocellular carcinoma cells with the hybrid vector,
human hepatocellular carcinoma cell lines (Hep3B and Huh-7)
were infected with HC-Ad-AFP-mIL-12 or HC-Ad-AFP-SFV-mIL-12.
A steady increase in mIL-12 expression from days 1 to 4
postinfection was observed in cells infected with HC-Ad-AFP-
SFV-mIL-12 (Supplementary Fig. S2). However, at day 5 postinfec-
tion, the mIL-12 level was stabilized or slightly reduced. In cells
infected with HC-Ad-AFP-mIL-12, the level of expression was much
lower although a slight increase of mIL-12 production was
observed along time in culture (Supplementary Fig. S2).
Induction of cell death after infection of hepatocellular
carcinoma cells with hybrid vectors in vitro . It has been
reported that replication of SFV vectors induces apoptotic cell
death in most cells of vertebrate origin (21). To check if the hybrid
vector also induced apoptosis in hepatocellular carcinoma cells,
Hep3B and McA-RH7777 cells, which express AFP, were infected
Gene Therapy of Liver Cancer with a Hybrid Vector
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with HC-Ad-AFP-SFV-mIL-12 or HC-Ad-AFP-SFV-LacZ vectors. As
shown in Fig. 3A , survival at day 5 postinfection was <20% in cells
infected with either vector. However, infection of the same cells
with HC-Ad-AFP-mIL-12, HC-Ad-AFP-LacZ, or with control vector
AdCMV-mIL-12 did not affect cell survival.
Expression of SFV Rep in hepatocellular carcinoma cells
infected with hybrid vectors in vitro . Expression of SFV Rep was
examined in human hepatocellular carcinoma (Hep3B and Huh-7)
and in AFP-nonexpressing (A549, SK-Hep-1, MHC1, and clone 9)
cells infected with HC-Ad-AFP vectors by immunofluorescence
using a specific mAb. Only human hepatocellular carcinoma cells
infected with HC-Ad-AFP-SFV-mIL-12 displayed a strong cytoplas-
mic staining for Rep (Fig. 3D). In contrast, human hepatocellular
carcinoma cells infected with HC-Ad-AFP-mIL-12 or AFP-non-
expressing cells infected with either vector did not show any
staining (Fig. 3B, F, and H). Similar data was observed when human
hepatocellular carcinoma cells were infected with HC-Ad-AFP-SFV-
LacZ and HC-Ad-AFP-LacZ (data not shown).
Replication of SFV RNA in hepatocellular carcinoma cells
infected with hybrid vectors in vitro. Replication of SFV RNA
was examined in human hepatocellular carcinoma cells (Hep3B)
and in AFP-nonexpressing cells (clone 9 or SK-Hep-1) infected with
HC-Ad-AFP-SFV-mIL-12, HC-Ad-AFP-mIL-12, or mock infected.
Only human hepatocellular carcinoma cells infected with hybrid
vector HC-Ad-AFP-SFV-mIL-12 showed two specific bands that
corresponded to the size of genomic and subgenomic RNAs derived
from SFV-IL-12 (Fig. 3J, lane 2). These bands were also detected in
BHK cells infected with SFV-IL-12, used as a positive control
(Fig. 3J, lane 1 ). No SFV RNAs were detected in human
hepatocellular carcinoma cells infected with HC-Ad-AFP-mIL-12
or in AFP-nonexpressing cells infected with either vector.
Gene transfer efficiency and induction of apoptosis in
human hepatocellular carcinoma tumors by hybrid vectors. To
study the transduction efficiency of the hybrid vectors in vivo , we
used a model of human hepatocellular carcinoma based on s.c.
implantation of Huh-7 cells in BALB/c nude mice. When tumors
reached 6 to 8 mm in diameter, animals were injected intra-
tumorally with 1  1010 vp of HC-Ad-AFP-SFV-LacZ or HC-Ad-
AFP-LacZ as control. As shown in Fig. 4A , there was a weak
transgene expression in tumor sections in animals receiving
HC-Ad-AFP-LacZ. In contrast, very strong expression of LacZ
was found in tumor sections from animals that had received
HC-Ad-AFP-SFV-LacZ (Fig. 4B). No transgene expression was
observed in liver sections from animals that had received either
Figure 3. Induction of cell death and SFV replication in hepatocellular
carcinoma cells infected with hybrid vectors in vitro. A, induction of cell death.
Hep3B and McA-RH7777 cells were infected with HC-Ad-AFP-mIL-12,
HC-Ad-AFP-SFV-mIL-12, HC-Ad-AFP-LacZ, HC-Ad-AFP-SFV-LacZ, or control
vector AdCMV-mIL-12. Five days after infection, cell survival was measured
by MTT assay. Cell survival is shown as the percentage of live cells in infected
wells related to the number of live cells in noninfected control wells (control ).
B to I, expression of SFV Rep. Hepatocellular carcinoma cells (Hep3B, B-E)
and non–hepatocellular carcinoma cells (A549, F-I ) were infected with
HC-Ad-AFP-mIL-12 (B, C, F , and G ) or HC-Ad-AFP-SFV-mIL-12 (D, E, H ,
and I ) at ppc 1,000. Two days after infection, cells were subjected to
immunocytochemistry by immunofluorescense with a Rep-specific antibody.
Rep-expressing cells were visualized with an FITC filter (B, D, F , and H ),
whereas DAPI-stained nuclei from all cells were visualized with a UV filter
(C, E, G , and I ). J, replication of SFV RNA. Hepatocellular carcinoma (Hep3B)
and non–hepatocellular carcinoma cells (clone 9) were infected with adenoviral
vectors at ppc 1,000; 2 days postinfection, total RNA was extracted and
analyzed by Northern blot using a 32P-labeled oligonucleotide specific
for SFV (top ) or a 32P-labeled oligonucleotide specific for h-actin (bottom ).
Lane 1, BHK cells infected with SFV-IL-12, used as a positive control;
lanes 2 to 4, Hep3B cells; lanes 6 to 8, clone 9. Cells were infected with
HC-Ad-AFP-SFV-mIL-12 (lanes 2 and 6), HC-Ad-AFP-mIL-12 (lanes 3 and 7),
or mock infected (lanes 4 and 8). Lane 5 was not loaded.
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HC-Ad-AFP-LacZ or HC-Ad-AFP-SFV-LacZ (data not shown).
Sections of the tumor nodules treated with the adenoviral vectors
were also analyzed by TUNEL to study whether hybrid vectors
could cause apoptotic cell death. No signal of apoptosis was
observed in samples from animals given HC-Ad-AFP-LacZ
(Fig. 4C). In contrast, there was a dramatic induction of cell
apoptosis in tumors from animals receiving HC-Ad-AFP-SFV-LacZ
(Fig. 4D). These data indicate that hybrid vectors do not only
specifically induce gene expression in tumor cells at high level but
also selectively cause cell death.
Specificity of hybrid vectors in vivo . To further show the
specificity of hybrid vectors, 1010 vp of HC-Ad-AFP-LacZ, HC-Ad-
AFP-SFV-LacZ, or control vector AdCMV-LacZ were administered
i.v. to BALB/c mice. As shown in Fig. 4E-F, neither HC-Ad-AFP-
LacZ nor HC-Ad-AFP-SFV-LacZ vectors were able to induce any
detectable transgene expression in liver tissue. However, in animals
receiving AdCMV-LacZ, a high proportion of h-galactosidase-
positive cells was observed in liver sections (Fig. 4G). These data
further confirm that transgene expression from hybrid vectors is
specifically confined to tumor cells.
Antitumoral efficacy and toxicity of hybrid vectors in
orthotopic hepatocellular carcinoma in Buffalo rats. To
investigate the antitumoral efficacy of the hybrid vector carrying
mIL-12, orthotopic hepatocellular carcinomas were established in
Buffalo rats by implantation of rat McA-RH7777 cells into the liver.
This model was chosen because McA-RH7777 cells have been
reported to express AFP (28). Our data showed that animals
receiving HC-Ad-AFP-mIL-12 had a reduced tumor size (Fig. 5A)
compared with control animals that experienced a steady increase
of tumor size along the experiment. However, treatment with HC-
Ad-AFP-SFV-mIL-12 resulted in complete tumor regression in 4 of
12 treated rats and partial tumor regression in the rest of animals
(Fig. 5A). In animals receiving SFV-mIL-12, a complete tumor
regression was observed in 50% of treated animals (Fig. 5A). The
Figure 4. Gene transfer efficiency and induction of apoptosis
by hybrid vectors in Huh-7 tumors. Human Huh-7 tumors
established in nude mice were treated by intratumoral injection of
HC-Ad-AFP-LacZ (n = 4) or HC-Ad-AFP-SFV-LacZ (n = 4) at
1  1010 vp/animal. Three days after virus administration, mice
were sacrificed and tumor and liver sections were analyzed for
transgene expression by X-Gal staining and for cell apoptosis by
TUNEL. A and C, microphotographs from tumors receiving
HC-Ad-AFP-LacZ. B and D, microphotographs from tumors
receiving HC-Ad-AFP-SFV-LacZ. A and B, stained by X-Gal; C
and D, stained by TUNEL. Original magnification, 200. E to G,
specificity of hybrid vectors in vivo . BALB/c mice were
administered i.v. with HC-Ad-AFP-LacZ (n = 4), HC-Ad-AFP-SFV-
LacZ (n = 4), or AdCMV-LacZ at 1  1010vp/animal. Liver
sections were stained with X-Gal. E to G, representative
photomicrographs from liver sections of animals receiving
HC-Ad-AFP-LacZ, HC-Ad-AFP-SFV-LacZ, or AdCMV-LacZ,
respectively. Original magnification, 200.
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mean value for tumor size in this group was comparable with the
one in animals treated with HC-Ad-AFP-SFV-mIL-12 (Fig. 5B). In
contrast, animals treated with SFV-LacZ had similar tumor growth
as that observed in control animals. Importantly, treatment with
HC-Ad-AFP-SFV-mIL-12 induced long-term survival in 50% of
treated animals, whereas treatment with HC-Ad-AFP-mIL-12 or
SFV-LacZ only increased survival slightly (Fig. 5C).
To evaluate the possible toxicity associated with the administra-
tion of vectors in vivo , we analyzed serum levels of transaminases
[alanine aminotransferase (ALT) and aspartate aminotransferase
(AST)] and GGT in tumor-bearing animals receiving either 2  1011
vp of hybrid vectors or 108 IU of SFV-mIL-12 at days 4 and 8 after
therapy. As shown in Fig. 6A to C , rats treated with HC-Ad-AFP-
mIL-12 (n = 12) or HC-Ad-AFP-SFV-mIL-12 (n = 12) showed similar
levels of transaminases and GGT compared with control animals
receiving saline (n = 6). However, the levels of transaminases and
GGT in animals treated with SFV-mIL-12 were significantly higher
than those of other groups (P < 0.05). In accordance with these
results, no IL-12 could be detected in serum from rats receiving
either HC-Ad-AFP-mIL-12 or HC-Ad-AFP-SFV-mIL-12 vectors, in
contrast with animals that had received SFV-mIL-12 where low
levels of IL-12 were detected at day 4 (data not shown).
Furthermore, histologic examination of liver sections showed a
normal structure without inflammation in those animals receiving
either saline, HC-Ad-AFP-mIL-12, or HC-Ad-AFP-SFV-mIL-12 vec-
tors (Fig. 6D-F). However, moderate inflammation with mononu-
clear cell infiltration was observed in liver sections from rats treated
with SFV-mIL-12 (Fig. 6G). These data suggest that the hybrid HC-
Ad-AFP-SFV-mIL-12 vector does not cause liver toxicity, whereas
the SFV-mIL-12 vector can induce liver damage.
Discussion
To combine safety and efficacy in cancer gene therapy, it is
necessary for the therapeutic transgenic protein to be expressed at
high level only in the treated tumor. Although specific transgene
expression in tumor cells can be accomplished by using tumor-
specific promoters, high levels of gene expression are usually hard to
reach with these rather weak promoters (8–11). In this study, we
have developed a novel strategy to potently increase transgene
expression specifically in hepatocellular carcinoma by placing a
recombinant alphavirus replicon under the transcriptional control
of a tumor-specific promoter. We have selected the AFP promoter
and enhancer because AFP is expressed in a high proportion of
primary liver tumors (11, 29, 30). The idea was that once the
promoter initiates the transcription of the SFV replicon, this self-
replicating RNA may induce high production of subgenomic RNA
and transgenic protein. The AFP-SFV replicon containing the mIL-
12 or LacZ genes downstream of the subgenomic promoter was
introduced into a gutless adenovirus. This type of vector was
selected for two reasons: (a) it can accommodate large expression
cassettes and (b) it exhibits strong tropism for liver cells and high
infectivity of liver-derived tumor cells. Thus, the rationale behind
the development of the HC-Ad-SFV hybrid vector was the possibility
of combining the following in a single vector: (a) high infectivity, by
using an adenoviral scaffold; (b) high level of transgene expression
Figure 5. Treatment of established hepatocellular carcinoma tumors
with hybrid vectors. Orthotopic hepatocellular carcinoma tumors were
established by intrahepatic implantation of rat hepatocellular
carcinoma cell line McA-RH7777. When tumor size reached 7 to
10 mm in diameter, animals were treated with 2  1011 vp of
HC-Ad-AFP-mIL-12 (n = 12), HC-Ad-AFP-SFV-mIL-12 (n = 12),
108 IU of SFV-mIL-12 (n = 8), SFV-LacZ (n = 5), or saline (n = 6)
as control. Tumor size in each individual animal was measured on the
15th and 30th day after virus administration. A, tumor size evolution in
individual animals from groups receiving saline, SFV-LacZ,
SFV-mIL-12, HC-Ad-AFV-mIL-12, or HC-Ad-AFP-SFV-mIL-12. B,
mean tumor size of each group. C, animal survival rate.
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and induction of apoptosis by using a SFV replicon; and (c) tumor
specificity by using a tumor-specific promoter driving the
transcription of the self-replicating SFV vector.
Data presented here show that both reporter gene LacZ and
therapeutic gene mIL-12 could be specifically expressed at very
high levels in human hepatocellular carcinoma tumor cells after
infection with hybrid HC-Ad-SFV vectors. The observed expression
levels were comparable with those induced by the strong universal
CMV promoter. In contrast, very low level of transgenic protein
could be observed in hepatocellular carcinoma tumor cells after
infection with conventional HC-Ad vectors in which transgenes
were placed directly under the transcriptional control of the AFP
promoter and enhancer. Most importantly, our data showed that
in AFP-nonexpressing cells, no transgene expression could be
detected after infection with either hybrid or conventional AFP
vectors either in vitro or in vivo . In accordance with these results,
SFV replicase was also being expressed specifically in hepatocel-
lular carcinoma cells infected with hybrid vectors. The detection of
SFV subgenomic RNA specifically in hepatocellular carcinoma cells
infected with HC-Ad-AFP-SFV vector provided additional evidence
of SFV RNA replication in these cells. These data indicated that
despite the use of a weak promoter, the SFV replicon is able to
induce high level of transgene expression without affecting the
tissue specificity of the selected promoter. In addition, we have
observed that the transgene expression provided by the hybrid
vector increased steadily in hepatocellular carcinoma cells after
infection during 4 days, reaching a plateau at day 5, probably due to
apoptotic cell death of the infected cells. In contrast, the expression
level induced by conventional HC-Ad vectors was always much
lower than with the hybrid vector increasing slightly during the
period of study.
Alphavirus replication induces apoptosis in most cells from
vertebrate origin by mechanisms that are not yet completely
understood (21, 31). Because induction of cell death correlates
with a high level of SFV RNA replication, it was of great interest
to check if apoptosis was also being induced in cells infected with
hybrid vectors. Several observations led to the conclusion that this
was the case. First, it was observed that some hepatocellular
carcinoma tumor cells showed a cytopathic effect at 2 days after
infection with hybrid vectors, whereas cells infected with control
vectors seemed to be normal. Furthermore, we found that at day 5
postinfection, cell survival was <20% in hepatocellular carcinoma
cells infected with the hybrid HC-Ad-SFV vectors, whereas there was
no reduction in viability in cells transduced with control vectors.
A third proof of evidence came from TUNEL studies done in
xenografted Huh-7 tumors infected with HC-Ad-AFP-SFV-LacZ
vector, where many cells experienced apoptosis after in vivo
infection. The ability of hybrid vectors to induce tumor cell
apoptosis may contribute to their antitumor efficiency through the
release of apoptotic bodies and facilitation of presentation of tumor
antigens to the immune system (12, 13, 32). In fact, the apoptotic
property of alphavirus vectors has been used by itself to mediate
antitumoral responses by treating tumors with repetitive high
doses of SFV vectors expressing reporter genes (33). However, in
the present study, as well as in previous publications (24), it was
shown that at the doses thatwere used, the cytopathic effect induced
Figure 6. Toxicity of hybrid vectors. Orthotopic liver tumors were treated with
2  1011 vp of HC-Ad-AFP-mIL-12, HC-Ad-AFP-SFV-mIL-12, 108 IU of
SFV-mIL-12, or saline as control. Serum samples were collected at days 4 and
8 after treatment for determination of ALT (A), AST (B), and GGT (C ). *, P < 0.05;
**, P < 0.01, compared with control group by Mann-Whitney test. D to G,
photomicrographs of liver sections stained with H&E corresponding to control
rats receiving saline (D ); HC-Ad-AFP-mIL-12 (E); HC-Ad-AFP-SFV-mIL-12 (F );
or SFV-mIL-12 (G). Original magnification, 200 (D-G ).
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by the replication of SFV was not enough by itself to induce a good
antitumoral response; the expression of antitumoral cytokines, such
as IL-12, is also necessary to generate a good therapeutic effect. This
could probably be due to the fact that when no cytokines are
expressed from the vector, a very high transduction efficiency is
needed in the tumor to promote a therapeutic response.
Our in vivo studies in an animal model of s.c. hepatocellular
carcinoma tumor further showed that the transduction efficiency
of the hybrid vector containing LacZ was much higher than that
of conventional HC-Ad-AFP-LacZ vector. Importantly, transgene
expression was not observed in liver from animals receiving
either intratumoral or systemic administration of the hybrid
vector. The potency and toxicity of HC-Ad-AFP-SFV-mIL-12 was
evaluated in an orthotopic rat hepatocellular carcinoma model.
The use of this vector resulted in complete tumor regression in
33% of tumor-bearing rats and induced long-term survival in 50%
of animals. In contrast, all animals treated with HC-Ad-AFP-mIL-
12 (devoid of SFV replicon) were dead by day 70 after treatment.
Interestingly, when we used the SFV-mIL-12 vector directly,
outside the adenoviral scaffold and, therefore, without the
transcriptional restriction provided by the AFP promoter, we
found an efficacy comparable with the one obtained with HC-Ad-
AFP-SFV-mIL-12. Although the induction of apoptosis per se
could be responsible for the antitumoral effect induced by HC-
Ad-AFP-SFV-mIL-12 and SFV-mIL-12, the fact that SFV-LacZ
did not induce any significant therapeutic effect suggests that
expression of IL-12 is also necessary to achieve a good anti-
tumoral response.
When animals were assayed for toxicity, we observed that
although there was no change in serum transaminases nor in liver
histology in rats that received HC-Ad-AFP-SFV-mIL-12, a signifi-
cant increase of liver enzymes and a liver inflammatory reaction
was found in animals treated with SFV-mIL-12. This toxicity may
result from the escape of viral particles to the general circulation,
leading to infection of the liver and other organs with production of
mIL-12 at high levels outside the treated lesion and induction of
apoptosis in transduced cells. More detailed toxicologic studies will
be needed to verify whether liver toxicity associated with SFV
vectors could limit their clinical application. These observations
reveal that the hybrid HC-Ad-AFP-SFV vector displays potent
antitumor effects together with a high safety profile, being superior
to other nontargeted vectors and indicating that it may represent
a useful tool for clinical applications.
Hepatocellular carcinoma is usually accompanied by liver
cirrhosis and it has been observed that AFP can be expressed
in some cases in cirrhotic liver (34). Theoretically, this could
compromise the specificity of the hybrid HC-Ad-AFP-SFV vector.
However, results from our group using positron emission tomo-
graphy to detect transgene expression in a clinical trial conducted
to treat hepatocellular carcinoma with an adenoviral vector
encoding HSV-tk showed that after intratumoral injection, the
transgene is only expressed in the tumor nodule with complete
sparing of the surrounding cirrhotic liver tissue (35). This finding
could be explained by the fact that the injected vector escaping to
the general circulation failed to infect the cirrhotic liver due to the
physical barrier formed by fibrotic tissue between vascular lumen
and hepatocytes. Some reports have also shown that cirrhotic liver
was difficult to be transduced by adenoviral vectors given by
intravascular route in an experimental animal model (36). As well
as AFP promoter/enhancer is used for hepatocellular carcinoma,
other promoters, such as prostate-specific antigen for prostate
cancer (37) or E2F and TERT for various types of tumors (38, 39),
could be used instead of AFP, adapting this new strategy to
different types of tumors.
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